385 related articles for article (PubMed ID: 8667045)
1. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET.
Piert M; Koeppe RA; Giordani B; Berent S; Kuhl DE
J Nucl Med; 1996 Feb; 37(2):201-8. PubMed ID: 8667045
[TBL] [Abstract][Full Text] [Related]
2. Determination of regional rate constants from dynamic FDG-PET studies in Parkinson's disease.
Piert M; Koeppe RA; Giordani B; Minoshima S; Kuhl DE
J Nucl Med; 1996 Jul; 37(7):1115-22. PubMed ID: 8965180
[TBL] [Abstract][Full Text] [Related]
3. Regional kinetic constants and cerebral metabolic rate for glucose in normal human volunteers determined by dynamic positron emission tomography of [18F]-2-fluoro-2-deoxy-D-glucose.
Heiss WD; Pawlik G; Herholz K; Wagner R; Göldner H; Wienhard K
J Cereb Blood Flow Metab; 1984 Jun; 4(2):212-23. PubMed ID: 6609929
[TBL] [Abstract][Full Text] [Related]
4. Diminished glucose transport in Alzheimer's disease: dynamic PET studies.
Jagust WJ; Seab JP; Huesman RH; Valk PE; Mathis CA; Reed BR; Coxson PG; Budinger TF
J Cereb Blood Flow Metab; 1991 Mar; 11(2):323-30. PubMed ID: 1997504
[TBL] [Abstract][Full Text] [Related]
5. Regional cerebral glucose transport and utilization in Alzheimer's disease.
Friedland RP; Jagust WJ; Huesman RH; Koss E; Knittel B; Mathis CA; Ober BA; Mazoyer BM; Budinger TF
Neurology; 1989 Nov; 39(11):1427-34. PubMed ID: 2812318
[TBL] [Abstract][Full Text] [Related]
6. Measurements of glucose phosphorylation with FDG and PET are not reduced by dephosphorylation of FDG-6-phosphate.
Kuwabara H; Gjedde A
J Nucl Med; 1991 Apr; 32(4):692-8. PubMed ID: 2013809
[TBL] [Abstract][Full Text] [Related]
7. Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease.
Ishii K; Sasaki M; Kitagaki H; Yamaji S; Sakamoto S; Matsuda K; Mori E
J Nucl Med; 1997 Jun; 38(6):925-8. PubMed ID: 9189143
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
Alexander GE; Chen K; Pietrini P; Rapoport SI; Reiman EM
Am J Psychiatry; 2002 May; 159(5):738-45. PubMed ID: 11986126
[TBL] [Abstract][Full Text] [Related]
9. Altered cerebral energy metabolism in Alzheimer's disease: a PET study.
Fukuyama H; Ogawa M; Yamauchi H; Yamaguchi S; Kimura J; Yonekura Y; Konishi J
J Nucl Med; 1994 Jan; 35(1):1-6. PubMed ID: 8271029
[TBL] [Abstract][Full Text] [Related]
10. Preferential metabolic involvement of visual cortical areas in a subtype of Alzheimer's disease: clinical implications.
Pietrini P; Furey ML; Graff-Radford N; Freo U; Alexander GE; Grady CL; Dani A; Mentis MJ; Schapiro MB
Am J Psychiatry; 1996 Oct; 153(10):1261-8. PubMed ID: 8831432
[TBL] [Abstract][Full Text] [Related]
11. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity.
Vander Borght T; Minoshima S; Giordani B; Foster NL; Frey KA; Berent S; Albin RL; Koeppe RA; Kuhl DE
J Nucl Med; 1997 May; 38(5):797-802. PubMed ID: 9170449
[TBL] [Abstract][Full Text] [Related]
12. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET.
Minoshima S; Frey KA; Koeppe RA; Foster NL; Kuhl DE
J Nucl Med; 1995 Jul; 36(7):1238-48. PubMed ID: 7790950
[TBL] [Abstract][Full Text] [Related]
13. Dynamic [18F]fluorodeoxyglucose positron emission tomography and hypometabolic zones in seizures: reduced capillary influx.
Cornford EM; Gee MN; Swartz BE; Mandelkern MA; Blahd WH; Landaw EM; Delgado-Escueta AV
Ann Neurol; 1998 Jun; 43(6):801-8. PubMed ID: 9629850
[TBL] [Abstract][Full Text] [Related]
14. PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer's disease.
Groom GN; Junck L; Foster NL; Frey KA; Kuhl DE
J Nucl Med; 1995 Dec; 36(12):2207-10. PubMed ID: 8523106
[TBL] [Abstract][Full Text] [Related]
15. Effect of selecting a fixed dephosphorylation rate on the estimation of rate constants and rCMRGlu from dynamic [18F] fluorodeoxyglucose/PET data.
Dhawan V; Moeller JR; Strother SC; Evans AC; Rottenberg DA
J Nucl Med; 1989 Sep; 30(9):1483-8. PubMed ID: 2788721
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography in patients with clinically diagnosed Alzheimer's disease.
McGeer PL; Kamo H; Harrop R; Li DK; Tuokko H; McGeer EG; Adam MJ; Ammann W; Beattie BL; Calne DB
CMAJ; 1986 Mar; 134(6):597-607. PubMed ID: 3512063
[TBL] [Abstract][Full Text] [Related]
17. [Cerebral glucose metabolism in dementia (PET-FDG study)].
Hatazawa J; Itoh M; Matsuzawa T
Rinsho Hoshasen; 1989 Oct; 34(11):1343-8. PubMed ID: 2601096
[TBL] [Abstract][Full Text] [Related]
18. Coronal reconstruction images of glucose metabolism in Alzheimer's disease.
Fukuyama H; Harada K; Yamauchi H; Miyoshi T; Yamaguchi S; Kimura J; Kameyama M; Senda M; Yonekura Y; Konishi J
J Neurol Sci; 1991 Dec; 106(2):128-34. PubMed ID: 1802960
[TBL] [Abstract][Full Text] [Related]
19. Errors introduced by tissue heterogeneity in estimation of local cerebral glucose utilization with current kinetic models of the [18F]fluorodeoxyglucose method.
Schmidt K; Lucignani G; Moresco RM; Rizzo G; Gilardi MC; Messa C; Colombo F; Fazio F; Sokoloff L
J Cereb Blood Flow Metab; 1992 Sep; 12(5):823-34. PubMed ID: 1506447
[TBL] [Abstract][Full Text] [Related]
20. Effects of human aging on patterns of local cerebral glucose utilization determined by the [18F]fluorodeoxyglucose method.
Kuhl DE; Metter EJ; Riege WH; Phelps ME
J Cereb Blood Flow Metab; 1982; 2(2):163-71. PubMed ID: 6978885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
